ENDRA Life Sciences (NDRA) EBITDA (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported EBITDA for 11 consecutive years, with -$2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 47.95% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$6.5 million (up 31.96% YoY), while the FY2025 annual figure was -$5.8 million, up 46.72% from the prior year.
• EBITDA declined to -$2.2 million in Q1 2026 per NDRA's latest filing, from -$1.6 million in the prior quarter.
• Across five years, EBITDA topped out at -$1.3 million in Q2 2025 and bottomed at -$4.3 million in Q4 2024.
• Historically, EBITDA has averaged -$2.5 million across 5 years, with a median of -$2.8 million in 2024.
• Annual changes were most pronounced in 2024 — EBITDA tumbled 194.75% — and 2025, when it jumped 62.25%.
• ENDRA Life Sciences' EBITDA stood at -$3.3 million in 2022, then soared by 56.0% to -$1.5 million in 2023, then sank by 194.75% to -$4.3 million in 2024, then surged by 62.25% to -$1.6 million in 2025, then sank by 34.01% to -$2.2 million in 2026.
• Business Quant data shows NDRA's EBITDA at -$2.2 million in Q1 2026, -$1.6 million in Q4 2025, and -$1.4 million in Q3 2025.